183 related articles for article (PubMed ID: 8063415)
1. Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.
Pier GB; DesJardin D; Grout M; Garner C; Bennett SE; Pekoe G; Fuller SA; Thornton MO; Harkonen WS; Miller HC
Infect Immun; 1994 Sep; 62(9):3972-9. PubMed ID: 8063415
[TBL] [Abstract][Full Text] [Related]
2. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine.
Theilacker C; Coleman FT; Mueschenborn S; Llosa N; Grout M; Pier GB
Infect Immun; 2003 Jul; 71(7):3875-84. PubMed ID: 12819072
[TBL] [Abstract][Full Text] [Related]
3. Rationale for development of immunotherapies that target mucoid Pseudomonas aeruginosa infection in cystic fibrosis patients.
Pier GB
Behring Inst Mitt; 1997 Feb; (98):350-60. PubMed ID: 9382760
[TBL] [Abstract][Full Text] [Related]
4. Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins.
Pier GB; Grout M; Desjardins D
J Immunol; 1991 Sep; 147(6):1869-76. PubMed ID: 1832427
[TBL] [Abstract][Full Text] [Related]
5. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients.
Meluleni GJ; Grout M; Evans DJ; Pier GB
J Immunol; 1995 Aug; 155(4):2029-38. PubMed ID: 7636254
[TBL] [Abstract][Full Text] [Related]
6. Immunogenic properties of Pseudomonas aeruginosa mucoid exopolysaccharide.
Garner CV; DesJardins D; Pier GB
Infect Immun; 1990 Jun; 58(6):1835-42. PubMed ID: 2140341
[TBL] [Abstract][Full Text] [Related]
7. Induction of opsonic antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide by an anti-idiotypic monoclonal antibody.
Schreiber JR; Pier GB; Grout M; Nixon K; Patawaran M
J Infect Dis; 1991 Sep; 164(3):507-14. PubMed ID: 1831226
[TBL] [Abstract][Full Text] [Related]
8. Biologic activities of antibodies to the neutral-polysaccharide component of the Pseudomonas aeruginosa lipopolysaccharide are blocked by O side chains and mucoid exopolysaccharide (alginate).
Hatano K; Goldberg JB; Pier GB
Infect Immun; 1995 Jan; 63(1):21-6. PubMed ID: 7528730
[TBL] [Abstract][Full Text] [Related]
9. Cross-sectional and longitudinal studies of naturally occurring antibodies to Pseudomonas aeruginosa in cystic fibrosis indicate absence of antibody-mediated protection and decline in opsonic quality after infection.
Tosi MF; Zakem-Cloud H; Demko CA; Schreiber JR; Stern RC; Konstan MW; Berger M
J Infect Dis; 1995 Aug; 172(2):453-61. PubMed ID: 7622889
[TBL] [Abstract][Full Text] [Related]
10. Nonspecific immunoglobulin synthesis and elevated IgG levels in rabbits immunized with mucoid exopolysaccharide from cystic fibrosis isolates of Pseudomonas aeruginosa.
Pier GB; Elcock ME
J Immunol; 1984 Aug; 133(2):734-9. PubMed ID: 6234359
[TBL] [Abstract][Full Text] [Related]
11. Polysaccharide antigens of Pseudomonas aeruginosa.
Pier GB
Rev Infect Dis; 1988; 10 Suppl 2():S337-40. PubMed ID: 3142017
[TBL] [Abstract][Full Text] [Related]
12. Antibody to Pseudomonas aeruginosa mucoid exopolysaccharide and to sodium alginate in cystic fibrosis serum.
Speert DP; Lawton D; Mutharia LM
Pediatr Res; 1984 May; 18(5):431-3. PubMed ID: 6233529
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and characterization of Pseudomonas aeruginosa alginate-tetanus toxoid conjugate.
Kashef N; Behzadian-Nejad Q; Najar-Peerayeh S; Mousavi-Hosseini K; Moazzeni M; Djavid GE
J Med Microbiol; 2006 Oct; 55(Pt 10):1441-1446. PubMed ID: 17005795
[TBL] [Abstract][Full Text] [Related]
14. Immune complexes from immunized mice and infected cystic fibrosis patients mediate murine and human T cell killing of hybridomas producing protective, opsonic antibody to Pseudomonas aeruginosa.
Pier GB; Takeda S; Grout M; Markham RB
J Clin Invest; 1993 Mar; 91(3):1079-87. PubMed ID: 8450038
[TBL] [Abstract][Full Text] [Related]
15. Opsonophagocytic killing antibody to Pseudomonas aeruginosa mucoid exopolysaccharide in older noncolonized patients with cystic fibrosis.
Pier GB; Saunders JM; Ames P; Edwards MS; Auerbach H; Goldfarb J; Speert DP; Hurwitch S
N Engl J Med; 1987 Sep; 317(13):793-8. PubMed ID: 2957591
[TBL] [Abstract][Full Text] [Related]
16. Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa.
Pier GB; Matthews WJ; Eardley DD
J Infect Dis; 1983 Mar; 147(3):494-503. PubMed ID: 6220094
[TBL] [Abstract][Full Text] [Related]
17. Alginate--its role in neutrophil responses and signal transduction towards mucoid Pseudomonas aeruginosa bacteria.
König B; Friedl P; Pedersen SS; König W
Int Arch Allergy Immunol; 1992; 99(1):98-106. PubMed ID: 1336422
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa surface polysaccharide vaccines. New therapeutic approaches from basic research.
Pier GB
Antibiot Chemother (1971); 1985; 36():157-67. PubMed ID: 3923913
[TBL] [Abstract][Full Text] [Related]
19. Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections.
Pier GB; Small GJ; Warren HB
Science; 1990 Aug; 249(4968):537-40. PubMed ID: 2116663
[TBL] [Abstract][Full Text] [Related]
20. Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide.
Ames P; DesJardins D; Pier GB
Infect Immun; 1985 Aug; 49(2):281-5. PubMed ID: 3160660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
